[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-unknown-primary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-unknown-primary":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,102,129,165,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":68,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100565188","phase-2-agnostic-therapy-in-rare-solid-tumors-100565188",false,"NCT06638931","Agnostic Therapy in Rare Solid Tumors","Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors","ANTARES","Inclusion Criteria\n\n1. Age 18 years or older.\n2. Patients with immunohistochemistry for PD-L1 with a combined positive score (CPS) of 10 or higher.\n3. Patients with progression or intolerance to already approved and accessible treatments for the specific neoplasm and population.\n4. Documented disease progression radiologically after the last routine treatment.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy can only be used as target lesions if they are confirmed to be progressing by imaging before enrollment.\n7. Male participants must meet at least one of the following conditions:\n\n   1. Considered infertile;\n   2. No fertile partner;\n   3. Has a fertile partner who agrees to follow contraceptive guidance throughout the study period and for at least 6 months after the last dose of Nivolumab;\n\n      and\n   4. Agrees to abstain from sperm donation throughout the study period and for at least 6 months after the last dose of Nivolumab.\n8. Female participants must meet at least one of the following conditions:\n\n   1. Considered infertile;\n   2. Agrees to follow contraceptive guidance throughout the study period and for at least 6 months after the last dose of Nivolumab;\n9. Estimated life expectancy greater than 12 weeks, as determined by the investigator or delegated sub-investigator.\n10. Preserved organ functions defined by:\n\n    * Absolute neutrophil count ≥ 1,000;\n    * Hemoglobin ≥ 8.0 g\u002FdL (patients may receive transfusions to reach this level);\n    * Platelet count ≥ 100,000;\n    * Total bilirubin ≤ 1.5 × Upper Limit of Normal (ULN), or ≤ 3.0 × ULN for patients with Gilbert's syndrome;\n    * Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN in the presence of liver metastases);\n    * Creatinine clearance \\> 30 mL\u002Fmin (estimated by Cockcroft-Gault).\n11. Diagnosis of rare cancer (List I) confirmed by histopathological examination, with the possibility of including other types of rare tumors (incidence of less than 6 in every 100,000) after careful evaluation and approval by the study board.\n\n    * List I:\n\n      * Urachal adenocarcinoma\n      * Parathyroid carcinoma\n      * Nasopharyngeal epithelial tumors\n      * Fibrolamellar carcinoma of any primary site\n      * Angiosarcoma of any primary site\n      * Secretory breast carcinoma\n      * Anal cancer\n      * Metaplastic breast carcinoma\n      * Chromophobe renal carcinoma, Microphthalmia-associated Transcription Factor (MiT) family translocation renal carcinoma; renal carcinoma with Fumarate Hydratase (FH) or Succinate Dehydrogenase (SDH) deficiency\n      * Carcinosarcoma of any primary site\n      * Small intestine cancer\n      * Cholangiocarcinoma\n      * Sertoli-Leydig cell tumors\n      * Cervical cancer of non-epidermoid histology\n      * Tracheal epithelial tumors\n      * Non-cystadenoma salivary gland tumors\n      * Mesothelioma of any site\n      * Neuroblastoma\n      * Adrenal cancer\n      * Penile cancer\n      * Apocrine carcinoma\n      * Fibrosarcoma of any primary site\n      * Cancer of unknown primary site\n      * Hemangioblastoma of any primary site\n      * Thyroid cancer\n      * Hepatoblastoma\n      * Fallopian tube cancer\n      * Leiomyosarcoma of any primary site\n      * Vaginal cancer\n      * Neurofibrosarcoma of any primary site\n      * Gallbladder cancer\n      * Osteosarcoma of any primary site\n      * Bile duct cancer\n      * Clear cell endometrial carcinoma\n      * Yolk sac tumor of any primary site\n      * Non-epidermoid bladder cancer\n      * Vulvar cancer\n      * Kaposi's sarcoma\n      * Epithelial ovarian cancer\n      * Soft tissue sarcoma\n      * Urethral cancer\n      * Granulosa cell tumor of any primary site\n      * Cystadenoma carcinoma\n      * Primitive neuroectodermal tumor of any primary site\n      * Pure or mixed neuroendocrine tumors with neuroendocrine component\n      * Trophoblastic tumor\n\nExclusion Criteria\n\n1. Previous treatment lines with immunotherapy (immune checkpoint inhibitors).\n2. Pregnant or breastfeeding individuals.\n3. Limiting comorbidity, in the opinion of the investigator.\n4. Active infection.\n5. Major surgery within the last 4 weeks.\n6. Functional class II or greater heart failure.\n7. Myocardial infarction or stroke within the last 6 months.\n8. History of pulmonary fibrosis or pneumonitis.\n9. Autoimmune diseases, except for patients with vitiligo and\u002For controlled thyroid\u002Fhypothyroidism without the use of immunosuppressors.\n10. Second invasive primary tumor diagnosed in the last 3 years and\u002For with active disease, except for localized skin tumors (non-melanoma) that have been treated with curative intent.\n11. Patients with prolonged QT interval.\n12. Uncontrolled Central Nervous System (CNS) metastases. Patients who have previously received local treatment, such as radiotherapy, will be eligible if clinical and radiological stability is demonstrated in the 2 weeks prior to the start of treatment. Patients must not be using corticosteroids for managing CNS disease.\n13. Presence of meningeal carcinomatosis.\n14. Worsening renal and liver function in the 14 days prior to enrollment.\n15. History of solid organ transplantation with or without immunosuppression.\n16. Patients with untreated acquired immunodeficiency. Immunocompromised patients may be included as long as they do not have active opportunistic disease and\u002For active infection, after thorough clinical evaluation by the investigator or sub-investigator. HIV-positive patients must have documented undetectable viral load prior to inclusion.\n17. Chronic use of corticosteroids at doses greater than 10 mg\u002Fday of prednisone or equivalent. Patients with adrenal insufficiency of non-autoimmune etiology (e.g., previous bilateral adrenalectomy) may be included if they are clinically compensated with 10 mg\u002Fday of prednisone or equivalent or less.","ALL","18 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.\n\nThe study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and treatment will last for up to 12 months. The study will assess objective response, progression-free survival, and biomarkers such as PD-L1, ctDNA, and microvesicles, in a multicenter collaborative effort to provide innovative therapeutic options for this underrepresented population",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67],"Urachal Cancer","Parathyroid Carcinoma","Fibrolamellar Carcinoma","Angiosarcoma","Secretory Carcinoma of Breast","Anal Neoplasms","Metaplastic Breast Carcinoma","Translocation Renal Cell Carcinoma","Carcinosarcoma","Small Intestine Neoplasms","Cholangiocarcinoma","Sertoli-Leydig Cell Tumor","Adenoid Cystic Carcinoma","Mesothelioma","Neuroblastoma","Adrenal Gland Neoplasms","Penile Neoplasms","Apocrine Carcinoma","Fibrosarcoma","Cancer of Unknown Primary","Hemangioblastoma","Thyroid Neoplasms","Hepatoblastoma","Fallopian Tube Neoplasms","Leiomyosarcoma","Vaginal Neoplasms","Neurofibrosarcoma","Gallbladder Neoplasms","Osteosarcoma","Biliary Tract Neoplasms","Clear Cell Endometrial Cancer","Yolk Sac Tumor","Vulvar Neoplasms","Kaposi Sarcoma","Ovarian Epithelial Cancer","Soft Tissue Sarcoma","Urethral Neoplasms","Granulosa Cell Tumor","Primitive Neuroectodermal Tumor","Neuroendocrine Tumors","Trophoblastic Tumor",[69,28,70,29,30,71,72,33,73,35,74,37,75,76,77,78,40,41,79,80,44,45,46,47,81,49,82,51,83,53,84,55,85,57,58,86,87,60,61,62,88,64,39,65,66,67],"Urachal Adenocarcinoma","Nasopharyngeal Epithelial Tumors","Secretory Breast Carcinoma","Anal Cancer","Chromophobe Renal Carcinoma","Small Intestine Cancer","Sertoli-Leydig Cell Tumors","Non-Squamous Cervical Neoplasm","Tracheal Epithelial Tumors","Non-Adenoid Cystic Salivary Tumors","Adrenal Neoplasm","Penile Cancer","Thyroid Cancer","Fallopian Tube Cancer","Vaginal Cancer","Gallbladder Cancer","Biliary Tract Cancer","Non-Squamous Bladder Cancer","Vulvar Cancer","Urethral Cancer","RECRUITING","2026-04-10",{"date":92,"type":93},"2026-04-15","ACTUAL",{"date":95,"type":93},"2024-07-16",{"date":97,"type":21},"2028-05",{"name":99,"class":100},"Instituto do Cancer do Estado de São Paulo","OTHER",8,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100569534","enabling-genomic-testing-in-cancer-of-unknown-primary-100569534","NCT06695494","Enabling Genomic Testing in Cancer of Unknown Primary","EGGCUP","Inclusion Criteria:\n\n1. Aged 16 years or over\n2. Written informed consent according to ICH\u002FGCP and national regulations\n3. ECOG Performance status 0-2\n4. Confirmed diagnosis of CUP as per the ESMO guidelines. Patients must have;\n\n   1. The local pathology reports confirming compatibility with CUP diagnosis and the associated slides used for the diagnosis\n   2. Discussion at a local CUP MDT confirming diagnosis\n5. Availability of archival tumour histological report\n6. Willingness to provide blood samples on up to two occasions during the study\n\nExclusion Criteria:\n\n1. Patient with an immunohistochemistry profile that provides a definitive clinical indication of a primary cancer with a specific treatment\n2. Known HIV, Hepatitis B, C positive, due to the difficulties in handling high-risk specimens\n3. Patients who are unable to provide fully informed written consent\n4. Presence of any medical, psychological, familial or sociological condition that, in the investigator's opinion, will hamper compliance with the study protocol and follow-up schedule\n5. Bleeding diathesis (patients' on anticoagulation are permitted to enter the trial if anticoagulation can be safely managed to enable blood sampling)\n6. Conditions in which blood sampling may increase risk of complications for the patients and\u002For investigator","16 Years",{"count":111,"type":21},100,"OBSERVATIONAL","Cancer of Unknown Primary (CUP) is where cancer cells are found in the body but the place the cancer began is not known. It is the 6th leading cause of cancer death in the UK and the prognosis is poor with a median survival of 6-9 months. There is a higher than average incidence of CUP in the North West (NW) of England (population of 7.4 million). Precision medicine has transformed treatment strategies in known tumour types, however in CUP there remains an urgent need to better understand CUP molecular characteristics to establish potential roles for novel therapeutic strategies. Treatment options remain limited due to difficulties in determining the primary site of the tumour and the lack of access to validated biomarkers. Access to good-quality tissue for molecular profiling remains a huge challenge in CUP. The emergence of liquid biopsies (sequence DNA in a blood test) as a source of biomarkers is also gaining rapid ground and this study aims to explore the potential utility of liquid biopsies in CUP.",[46,115],"Neoplasm, Unknown Primary",[117,118],"Cancer of unknown primary","Cancer","2026-03-24",{"date":121,"type":93},"2026-03-25",{"date":123,"type":93},"2024-08-15",{"date":125,"type":21},"2027-12-01",{"name":127,"class":100},"The Christie NHS Foundation Trust",6,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100626326","phase-2-phase-ii-trial-of-lu-177-fap-2286-in-patients-with-carcinoma-of-unknown-primary-100626326","NCT07434180","Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary","Lu-FAP CUP","Inclusion Criteria\n\nPatients must meet all the following criteria for trial entry:\n\n1. Patient has provided written informed consent\n2. Patients aged 18 years or over at Screening\n3. Diagnosed with CUP based on a diagnostic work-up, including, but not limited to; a detailed clinical assessment; a CT CAP; pathological review of tumour tissue; and other appropriate tests as per the Cancer Council Optimal Care Pathway guidelines.\n4. Progressed on 1st line platinum doublet chemotherapy +\u002F- immunotherapy +\u002F- antibody therapy\n5. 68Ga-FAPI-46 positive disease on 68Ga-FAPI-46-PET\u002FCT defined as 68Ga-FAPI-46 uptake at PET\u002FCT with SUVmax of ≥ 8 in at least 50% of target lesions and above surrounding background in the remaining target lesions\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix 1).\n7. Life expectancy greater than 3 months\n8. Adequate bone marrow, hepatic and renal function defined by the following laboratory results:\n\n   * Haemoglobin ≥ 90 g\u002FL independent of transfusion (no red blood cell transfusion within 4 weeks before the haematology Screening assessment)\n   * Absolute neutrophil count ≥ 1.5 x 109\u002FL\n   * Platelet count ≥ 100 x 109\u002FL\n   * Creatinine clearance (CrCl) ≥ 60 mL\u002Fmin calculated using the Cockcroft-Gault equation (Appendix 2)\n   * Serum bilirubin ≤ 1.5 x upper limit of normal (ULN); Patients with known Gilbert's disease may have a bilirubin ≥ 3.0 x ULN\n   * Aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2 x ULN (or ≤ 5 x ULN in the presence of liver metastases)\n9. Have measurable disease per RECIST1.1 (Appendix 3)\n10. Sexually active Patients are willing to use medically acceptable forms of barrier contraception as outlined in Section 8.1.5.1, during treatment and for 6 months following the last dose of treatment\n11. Women of childbearing potential (WCBP) must have a negative serum pregnancy test result\n12. Willing to undergo biopsies if disease is considered accessible and biopsy is feasible\n13. Willing and able to comply with all trial requirements, including all treatment and required assessments and follow-up procedures, in the Investigator's judgment\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria will be excluded from trial entry:\n\n  1. Uncontrolled medical or psychological conditions that may prevent commencement of systemic treatment\n  2. Symptomatic and\u002For untreated central nervous system metastases or leptomeningeal disease. Patients must be clinically stable for at least 4 weeks without steroid treatment\n  3. Surgical procedure (minor surgery ≤ 5 days, or major surgery ≤ 21 days) prior to registration or active infection requiring systemic treatment Note: Placement of vascular access devices, laparoscopy and prophylactic procedures to stabilise bone lesions are not considered major surgical procedures\n  4. Received anticancer treatment ≤ 14 days prior to registration (≤ 28 days prior in case of checkpoint inhibitor or other antibody therapies)\n  5. Severe impaired cardiac function (left ventricular ejection fraction \\\u003C 35%) or clinically significant uncontrolled cardiac disease\n  6. Severe urinary incontinence, voiding dysfunction, or unrelieved urinary obstruction\n  7. Ongoing AEs from anticancer treatment \\> Grade 1 as per CTCAE v5.0, with the exception of alopecia\n  8. Received prior radiopharmaceutical therapy or radioembolisation, or prior extensive external beam radiation therapy (EBRT) to bone marrow or any prior EBRT directly to kidney or received any EBRT within 2 weeks prior to registration\n  9. Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo procedures outlined in this protocol with reasonable safety\n  10. Prior cancer diagnosis with the exception of:\n\n      * Malignancy treated with curative intent and with no known active disease ≥ 3 years and of low potential risk of recurrence\n      * Adequately treated basal cell or squamous cell skin carcinoma or non-invasive melanoma\n      * Adequately treated non-muscle invasive bladder cancer (Tis, Ta and low grade T1 tumours)\n      * Adequately treated carcinoma in situ without evidence of disease\n  11. Cancer patients with incidental histologic findings of prostate cancer that, in the opinion of the Investigator, is not deemed to require active therapy (e.g., incidental prostate cancer identified following cystoprostatectomy that is tumour\u002Fnode\u002Fmetastasis stage ≤ pT2N0)\n  12. Greater than one prior line of systemic treatment\n  13. Known allergy or reaction to 18F, 68Ga or 177Lu radiopharmaceuticals\n  14. Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in the protocol with reasonable safety",{"count":137,"type":21},20,[24],"The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).",[46],[142,143,144,145,146,147,148,149,150,151,152,153],"cancer of unknown primary","177Lu-FAP-2286","Ga-FAPI-46","theranostic","FAP-2286","Fibroblast Activation Protein (FAP)","cancer-associated fibroblasts (CAF)","radiopharmaceutical","Targeted radioligand therapy (TRT)","Targeted radionuclide therapy","Peptide-Targeted Radioligand Therapy (PTRT)","Peptide Receptor Radionuclide Therapy (PRRT)","NOT_YET_RECRUITING","2026-02-22",{"date":157,"type":93},"2026-02-25",{"date":159,"type":21},"2026-06",{"date":161,"type":21},"2030-06",{"name":163,"class":100},"Peter MacCallum Cancer Centre, Australia",1,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":164},"100582889","phase-2-pucotenlimab-combined-with-mrg002-for-her2-positive-cancer-of-unknown-primary-100582889","NCT06869174","Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary","A Phase II Clinical Trial to Evaluate the Efficacy and Safety of Pucotenlimab in Combination with MRG002 in Treating HER2-positive Cancer of Unknown Primary","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form and comply with the protocol requirements.\n2. Subjects must be ≥18 years of age on the day of signing the informed consent form, with no gender restrictions.\n3. Expected survival of ≥3 months.\n4. Subjects with histologically confirmed squamous cell carcinoma, adenocarcinoma, or undifferentiated carcinoma of unknown primary origin by pathology laboratory, and who also meet the criteria of HER2 immunohistochemistry (IHC) 2+ or 3+. Subjects must have received at least one line of systemic therapy, including but not limited to targeted therapy, immunotherapy, chemotherapy, etc.\n5. Subjects must be able to provide a tumor specimen for pathological testing (paraffin block, paraffin-embedded sections, or fresh tissue sections are acceptable).\n6. Radiological evidence of disease progression during or after the most recent treatment, as confirmed by the investigator; according to RECIST 1.1 criteria, at least one measurable lesion at baseline.\n7. Adverse events (AEs) related to prior anti-tumor therapy must have resolved to ≤Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0), with the exception of alopecia, non-clinically significant or asymptomatic laboratory abnormalities.\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to dosing.\n9. No severe cardiac dysfunction, with a left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to dosing.\n10. Adequate organ function.\n11. Agree to contraception from the time of signing the informed consent form until 6 months after the last dose of the investigational drug. Women of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose of the investigational drug.\n\nExclusion Criteria:\n\n1. History of other primary malignancies.\n2. Received prohibited treatments as per the protocol.\n3. Untreated or unstable brain metastases, spinal metastases or compression, carcinomatous meningitis, or leptomeningeal metastases.\n4. Presence of ascites, pleural effusion, pericardial effusion that cannot be controlled by drainage methods, or subjects who require drainage to control third-space effusions within 14 days before dosing.\n5. Any severe or uncontrolled systemic disease, as judged by the investigator, including poorly controlled hypertension, uncontrolled diabetes, or signs of active bleeding.\n6. History of uncontrolled cardiac disease, including heart failure greater than NYHA Class II, unstable angina, myocardial infarction within the past year, clinically significant supraventricular or ventricular arrhythmias requiring treatment, or prolonged QT syndrome.\n7. Evidence of active infection, including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection; uncontrolled active bacterial, viral, fungal, rickettsial, or parasitic infections, unless treated and resolved before administration of the investigational drug.\n8. History of allergy to Pucotenlimab or any component of MRG002, or history of ≥Grade 3 allergic reaction to macromolecular protein preparations\u002Fmonoclonal antibodies.\n9. History of primary immunodeficiency or active autoimmune disease, current use of immunosuppressive agents, or systemic corticosteroid therapy (≥10 mg\u002Fday prednisone or equivalent), and continued use within 2 weeks before enrollment.\n10. History of or concurrent interstitial pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc.\n11. Positive serum pregnancy test or breastfeeding women who do not agree to adequate contraception during the study and for 6 months after receiving the investigational drug.\n12. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this clinical trial.",{"count":173,"type":21},50,[24],"This study is a single-arm, open-label, multicenter Phase II clinical trial designed to observe and evaluate the efficacy and safety of Pucotenlimab in combination with MRG002 in patients with HER2-positive (IHC 2+ or 3+) cancer of unknown primary.",[46],"2025-03-10",{"date":179,"type":93},"2025-03-12",{"date":181,"type":21},"2025-03-08",{"date":183,"type":21},"2028-08-08",{"name":185,"class":100},"Zhiguo Luo, MD, PhD",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":195,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":128},"100565633","18ff-fapi-pet-ct-to-identify-carcinoma-of-unknown-primary-origin-100565633","NCT06644716","[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin","FAPI for CUP","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Histologically-confirmed metastatic disease without identification of a primary tumor after standard diagnostic work-up, according to the national care pathway for CUP (in Dutch: Regionaal Zorgpad Primaire Tumor Onbekend), which includes at least an \\[18F\\]FDG PET-CT.\n\nExclusion Criteria:\n\n* Patients with metastasis from a known primary tumor.\n* Sarcomas, melanomas, germ cell tumors, neuroendocrine tumors and haematological malignancies whose exact site of origin is not established.\n* History of malignancy within 5 years prior to \\[18F\\]F-FAPI PET-CT scan, with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \\> 90%), such as adequately treated carcinoma in-situ of the cervix, nonmelanoma skin carcinoma, localized prostate cancer, ductal carcinoma in-situ, or Stage I uterine cancer.\n* Prior systemic therapy for the treatment of CUP.\n* Radiotherapy prior to \\[18F\\]F-FAPI PET-CT. Off note: radiotherapy with palliative intent for symptomatic skeleton lesions is allowed.\n* Impaired renal function, defined as eGFR (MDRD) \\\u003C25 ml\u002Fmin\u002F1,73 m2. An exception can be made in consultation with the treating physician.\n* WHO performance status \\>2 (Vademecum).\n* Pregnancy\u002Fbreastfeeding. For the latter, temporary discontinuation may be considered.\n* Known allergic reaction to therapeutic radiopharmaceuticals\n* Inability to lie still on the back for the duration of PET-CT\n* Any (other) condition, disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that may affect the interpretation of the results, or which might contribute substantially to the patient's experience of study burden (such as non-suppressible claustrophobia)","99 Years",{"count":173,"type":21},[196],"NA","The investigators will determine the proportion of CUP patients in whom the primary tumor can be identified by \\[18F\\]F-FAPI PET-CT.",[46],[200,201,46,202],"[18F]F-FAPI","PET-CT","Diagnostics","2025-02-10",{"date":205,"type":93},"2025-02-12",{"date":207,"type":93},"2024-07-19",{"date":209,"type":21},"2027-03",{"name":211,"class":100},"Erasmus Medical Center"]